Search | VHL Regional Portal

Altered prostaglandin E1 dosage during extracorporeal membrane oxygenation in a newborn with ductal-dependent congenital heart disease.

Stone, D M; Frattarelli, D A C; Karthikeyan, S; Johnson, Y R; Chintala, K.

Pediatr Cardiol ; 27(3): 360-3, 2006.

Article in English | MEDLINE | ID: mdl-16565906

ABSTRACT

We describe a neonate with ductal-dependent congenital heart disease on extracorporeal membrane oxygenation (ECMO) for persistent pulmonary hypertension, who required markedly high doses of prostaglandin E1 (PGE1) to maintain patency of the ductus arteriosus: The effects of ECMO on the pharmacokinetics of PGE1 are discussed.

Subject(s)

Alprostadil/administration & dosage , Extracorporeal Membrane Oxygenation , Heart Defects, Congenital/therapy , Pulmonary Valve Stenosis/therapy , Vasodilator Agents/administration & dosage , Alprostadil/metabolism , Ductus Arteriosus, Patent/diagnostic imaging , Female , Heart Defects, Congenital/diagnostic imaging , Humans , Hypertension, Pulmonary/congenital , Hypertension, Pulmonary/therapy , Infant, Newborn , Meconium Aspiration Syndrome/therapy , Ultrasonography , Vasodilator Agents/metabolism

ABSTRACT

Subject(s)

SEND TO:

SELECTION OF CITATIONS

SEARCH DETAIL